{
    "organizations": [],
    "uuid": "f14071a449e918d923e0ecf784a87fedf3d62feb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-clovis-oncology-says-rubraca-appro/brief-clovis-oncology-says-rubraca-approved-in-u-s-as-maintenance-treatment-of-recurrent-ovarian-cancer-idUSFWN1RJ0DE",
    "ord_in_thread": 0,
    "title": "BRIEF-Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 6 (Reuters) - Clovis Oncology Inc:\n* RUBRACA (RUCAPARIB) APPROVED IN THE U.S. AS MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER\n* U.S. FDA APPROVED RUBRACA TABLETS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CERTAIN TYPES OF RECURRENT CANCER\n* IN ADDITION TO GRANTING RUBRACA APPROVAL FDA CONVERTED APPROVAL OF INITIAL TREATMENT INDICATION FROM ACCELERATED TO REGULAR APPROVAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-06T20:55:00.000+03:00",
    "crawled": "2018-04-06T21:24:30.046+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "clovis",
        "oncology",
        "inc",
        "rubraca",
        "rucaparib",
        "approved",
        "maintenance",
        "treatment",
        "recurrent",
        "ovarian",
        "cancer",
        "fda",
        "approved",
        "rubraca",
        "tablet",
        "maintenance",
        "treatment",
        "adult",
        "patient",
        "certain",
        "type",
        "recurrent",
        "cancer",
        "addition",
        "granting",
        "rubraca",
        "approval",
        "fda",
        "converted",
        "approval",
        "initial",
        "treatment",
        "indication",
        "accelerated",
        "regular",
        "approval",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}